Model Danielle Lloyd reveals skin cancer diagnosis
Model Danielle Lloyd has revealed she has been diagnosed with a form of skin cancer.
In a video post to her Instagram Story on Friday, the 41-year-old TV personality said she was 'really shocked' to receive the news and would need to have an operation to determine if it has spread.
The mother-of-five used the opportunity to encourage others to see a doctor if they have noticed changes to their skin or body which could be a sign of cancer.
In the emotional video, she said: 'I don't really know how to say this and I didn't know whether to come on and say this but I just feel like I have to raise awareness about this happening to other people.
'Today I have been diagnosed with a form of skin cancer.
'And I just want to raise awareness for anyone who might think they've got something funny on their body, they see a mole that's growing that's not normal – please, please, please go to your doctor because honestly, you just never know.'
Lloyd said the Macmillan nurses at the hospital has 'really supported' her after she received the health news which had 'really shocked' her.
She added: 'Just honestly, not what I expected today. And I suppose not what anyone expects.
'But please guys look after your skin. Stay off sunbeds, wear factor 50. Just look after yourself because honestly you never know what's going to happen.'
The appearance of a lump or discoloured patch on the skin that continues to persist after a few weeks can be a sign of a form of skin cancer according to the NHS website.
A new mole or a change in an existing mole may also be signs of skin cancer.
The glamour model has been open about her health issues in the past including revealing she had vaginal rejuvenation treatment after her pregnancies left her struggling with incontinence.
She also previously discussed how she felt 'forced' to have cosmetic work done to her face after being trolled online about her looks.
During an appearance on ITV's Lorraine in 2018, Lloyd read out negative messages sent to her online, one of which described her as 'wrecked and trashy' and that she 'looks like a bloke'.
Lloyd rose to prominence as a beauty queen who was crowned Miss England 2004 and later Miss Great Britain 2006.
In 2007, Lloyd featured on the fifth series of the reality show Celebrity Big Brother.
She made it to the final three of Celebrity SAS: Who Dares Wins in 2023 alongside singer Gareth Gates and former health secretary Matt Hancock, but missed out on completing the course at the final stage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Wild About Sprouts® Celebrates World Food Safety Day with Breakthrough Cold-Grown® Technology That Redefines Safety and Nutrition
SCOTTSDALE, Ariz., June 6, 2025 /PRNewswire/ -- In honor of World Food Safety Day June 7, Wild About Sprouts® is shining a spotlight on its revolutionary Cold-Grown® process—an all-natural, patented innovation that has redefined food safety standards in the sprouting industry. With over 25 million containers sold pathogen-free and never part of any recall over its 8+ years, Wild About Sprouts is the only national sprout brand in the U.S., now proudly available in over 7,000 grocery stores across the country. Sprouts are among the most powerful, studied, and nutrient-dense superfoods on the planet. Yet for decades, their potential has been limited by persistent food safety concerns. Wild About Sprouts has solved that problem. Its Cold-Grown® process eliminates the risk of dangerous pathogens without the use of pesticides, herbicides, or chemical intervention, and uses 95% less water than traditional growing systems—making it one of the most sustainable solutions in fresh food today. "At Wild About Sprouts, food safety isn't a feature—it's the foundation," said Barry Didato, CEO of Rä Foods, parent company of Wild About Sprouts. "Our patented Cold-Grown® method is changing the way America eats—combining breakthrough safety with unmatched nutrition, delivering sprouts that contain up to 100 times more antioxidants, vitamins, and minerals than fully grown vegetables. Backed by over 2,000 studies, sprouts—especially broccoli sprouts—are rich in sulforaphane, a proven compound that supports the body's natural detox pathways, helps fight cancer, reduces inflammation, and shows promise in managing conditions like autism, diabetes, and neurodegenerative disease." Observed every year on June 7, World Food Safety Day highlights the importance of safe, accessible food for all. Wild About Sprouts is proud to lead this charge—proving that innovation can make clean, nutrient-packed, fresh foods not just possible, but scalable. "Wild About Sprouts has not only innovated with its Cold-Grown® technology—they've demonstrated an uncompromising commitment to public health," said Dr. Darin Detwiler, Food Safety Advocate, Professor and Author of Food Safety: Past, Present, and Predictions. "In an era when consumers demand both transparency and accountability, this company offers a clear model of how science and responsibility can align to create safer, more sustainable food systems. As we recognize World Food Safety Day, this kind of leadership is precisely what our food system needs to move from reaction to prevention." Whether tossed in a salad, layered on a sandwich, or blended into smoothies, Wild About Sprouts products offer an easy and delicious way to boost everyday nutrition—safely. For more information, visit or follow us on Instagram at @wild_about_sprouts. Wild About Sprouts is available at major retailers including Kroger, Walmart, Whole Foods Market, Sprouts Farmers Market, Albertsons, and many more. About Wild About Sprouts®Founded in 2016 and based in Scottsdale, Arizona, Wild About Sprouts is transforming the sprout industry with its science-backed, Cold-Grown® technology. As part of Rä Foods, a family office dedicated to better-for-you innovations, Wild About Sprouts is on a mission to deliver safe, delicious, nutrient-dense foods that Make America Healthy Again—one sprout at a time. View original content to download multimedia: SOURCE Rä Foods Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
New guidance launched in Ireland to support LGBTQ+ inclusion in mental health services
On June 6, a landmark new guidance was launched in Ireland to support staff working across mental health services in delivering more inclusive and equitable care to LGBTQ+ people. The document follows a review that highlighted how LGBTQ+ people face disproportionate levels of mental distress and unmet needs. Launched this morning at the LGBT Ireland National Conference, the guidance was produced by the Mental Health Commission with the aim of providing accessible guidance to mental health professionals. The document offers 'a deeper understanding' of the unique challenges that LGBTQ+ people face when accessing mental health services in Ireland. The guidance is based on an evidence review which highlighted the disproportionate levels of mental distress and unmet needs members of the LGBTQ+ community face, especially young people and trans individuals. The review found high rates of suicidal ideation, suicide attempts, and self-injury among LGBTQ+ people. Moreover, it highlighted a prevalence of anxiety, depression and eating disorders among gender and sexual minorities. These findings are supported by other research conducted in Ireland, including Belong To's Being LGBTQI+ in Ireland research and the My LGBTI+ Voice Matters study. These studies have highlighted how LGBTQ+ individuals experience a higher mental health burden in comparison to the general population. Visualizza questo post su Instagram Un post condiviso da Belong To (@belongtoyouthservices) LGBT Ireland welcomed the launch of the document, with CEO Paula Fagan saying it is a 'practical and much-needed' guidance. She added, 'This document is a vital step toward changing that trajectory by equipping staff with the tools and awareness they need to treat LGBTQIA+ service users with dignity, understanding and respect.' Chief Executive of the Mental Health Commission John Farrelly commented, saying: 'Many LGBTQIA+ people face significant mental health challenges that may not always be adequately addressed. 'Our guidance document is a response to that reality,' Farrelly added. 'It recognises that even where staff only have a surface-level understanding of LGBTQIA+ issues, their openness to learn and evolve is key to delivering truly inclusive care. This guidance is a call to action for mental health services to continue to become more responsive, affirming, and equitable.' Minister of State for Mental Health Mary Butler also welcomed the guidance, saying: 'Everyone who uses a mental health service should feel confident that they can access services which are inclusive, compassionate and completely non-judgmental. 'I encourage all those who deliver and work in mental health services to implement the important and practical steps contained in the guidance.' The post New guidance launched in Ireland to support LGBTQ+ inclusion in mental health services appeared first on GCN.
Yahoo
3 hours ago
- Yahoo
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
